Press Releases

BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission for Risto-cel

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027 U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle

In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment  Safety Profile of BEAM-301 Consistent with LNP-Based Therapies Beam Plans to Engage FDA on Potential Path to Approval;

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with

BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr.

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Wells

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S.

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU  BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies New Preclinical Data for